Works by Al-Ali, H.


Results: 66
    1
    2
    3
    4
    5

    TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo‐Moffitt study of 156 informative cases.

    Published in:
    American Journal of Hematology, 2023, v. 98, n. 4, p. E76, doi. 10.1002/ajh.26845
    By:
    • Fleti, Farah;
    • Chan, Onyee;
    • Singh, Amritpal;
    • Abdelmagid, Maymona G.;
    • Al‐Kali, Aref;
    • Elliott, Michelle A.;
    • Begna, Kebede H.;
    • Foran, James M.;
    • Badar, Talha;
    • Khera, Nandita;
    • Al Ali, Najla H.;
    • Padron, Eric;
    • Sallman, David A.;
    • Shah, Mithun;
    • Hiwase, Devendra;
    • Pardanani, Animesh;
    • Arber, Daniel A.;
    • Orazi, Attilio;
    • Reichard, Kaaren K.;
    • He, Rong
    Publication type:
    Article
    6
    7

    Autoimmune diseases and myelodysplastic syndromes.

    Published in:
    American Journal of Hematology, 2016, v. 91, n. 5, p. E280, doi. 10.1002/ajh.24333
    By:
    • Komrokji, Rami S.;
    • Kulasekararaj, Austin;
    • Al Ali, Najla H.;
    • Kordasti, Shahram;
    • Bart-Smith, Emily;
    • Craig, Benjamin M.;
    • Padron, Eric;
    • Zhang, Ling;
    • Lancet, Jeffrey E.;
    • Pinilla-Ibarz, Javier;
    • List, Alan F.;
    • Mufti, Ghulam J.;
    • Epling-Burnette, Pearlie K.
    Publication type:
    Article
    8
    9
    10

    Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.

    Published in:
    Cancer Medicine, 2016, v. 5, n. 7, p. 1694, doi. 10.1002/cam4.721
    By:
    • Rollison, Dana E.;
    • Shain, Kenneth H.;
    • Lee, Ji‐Hyun;
    • Hampras, Shalaka S.;
    • Fulp, William;
    • Fisher, Kate;
    • Al Ali, Najla H.;
    • Padron, Eric;
    • Lancet, Jeffrey;
    • Xu, Qiang;
    • Olesnyckyj, Martha;
    • Kenvin, Laurie;
    • Knight, Robert;
    • Dalton, William;
    • List, Alan;
    • Komrokji, Rami S.
    Publication type:
    Article
    11

    Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 2, p. 1, doi. 10.1038/s41408-022-00622-8
    By:
    • Mangaonkar, Abhishek A.;
    • Lasho, Terra L.;
    • Ketterling, Rhett P.;
    • Reichard, Kaaren K.;
    • Gangat, Naseema;
    • Al-Kali, Aref;
    • Begna, Kebede H.;
    • Pardanani, Animesh;
    • Al Ali, Najla H.;
    • Talati, Chetasi;
    • Sallman, David;
    • Padron, Eric;
    • Patnaik, Mrinal M.;
    • Tefferi, Ayalew;
    • Komrokji, Rami
    Publication type:
    Article
    12

    Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.

    Published in:
    2021
    By:
    • Kanagal-Shamanna, Rashmi;
    • Montalban-Bravo, Guillermo;
    • Katsonis, Panagiotis;
    • Sasaki, Koji;
    • Class, Caleb A.;
    • Jabbour, Elias;
    • Sallman, David;
    • Hunter, Anthony Michael;
    • Benton, Christopher;
    • Chien, Kelly S.;
    • Luthra, Rajyalakshmi;
    • Bueso-Ramos, Carlos E.;
    • Kadia, Tapan;
    • Andreeff, Michael;
    • Komrokji, Rami S.;
    • Al Ali, Najla H;
    • Short, Nicholas;
    • Daver, Naval;
    • Routbort, Mark J.;
    • Khoury, Joseph D.
    Publication type:
    Letter to the Editor
    13
    14
    15

    Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS.

    Published in:
    HemaSphere, 2025, v. 9, n. 1, p. 1, doi. 10.1002/hem3.70086
    By:
    • Consagra, Angela;
    • Lanino, Luca;
    • Al Ali, Najla H.;
    • Aguirre, Luis;
    • Xie, Zhuoer;
    • Chan, Onyee;
    • Andreossi, Gloria;
    • Raddi, Marco G.;
    • Rigodanza, Luca;
    • Sanna, Alessandro;
    • Mattiuz, Giorgio;
    • Tofacchi, Elena;
    • Amato, Cristina;
    • Tanturli, Michele;
    • De Pourcq, Sven;
    • Walker, Alison;
    • Kuykendall, Andrew;
    • Lancet, Jeffrey;
    • Padron, Eric;
    • Sallman, David A.
    Publication type:
    Article
    16
    17

    P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM].

    Published in:
    HemaSphere, 2022, v. 6, p. 940, doi. 10.1097/01.HS9.0000847068.32650.9b
    By:
    • Vannucchi, A.;
    • Mesa, R.;
    • Gerds, A.;
    • Al‐Ali, H. K.;
    • Lavie, D.;
    • Kuykendall, A.;
    • Grosicki, S.;
    • Iurlo, A.;
    • Goh, Y. T.;
    • Lazaroiu, M.;
    • Egyed, M.;
    • Fox, M. L.;
    • McLornan, D.;
    • Perkins, A.;
    • Yoon, S.‐S.;
    • Gupta, V.;
    • Kiladjian, J.‐J.;
    • Donahue, R.;
    • Kawashima, J.;
    • Verstovsek, S.
    Publication type:
    Article
    18

    P1030: MANIFEST‐2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE‐BLIND, ACTIVE‐CONTROL STUDY OF PELABRESIB (CPI‐0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR‐NAÏVE MYELOFIBROSIS PATIENTS.

    Published in:
    HemaSphere, 2022, v. 6, p. 920, doi. 10.1097/01.HS9.0000846988.26018.ea
    By:
    • Harrison, C.;
    • Rampal, R. K.;
    • Gupta, V.;
    • Verstovsek, S.;
    • Talpaz, M.;
    • Kiladjian, J.‐J.;
    • Mesa, R.;
    • Kuykendall, A.;
    • Vannucchi, A.;
    • Palandri, F.;
    • Grosicki, S.;
    • Devos, T.;
    • Jourdan, E.;
    • Wondergem, M. J.;
    • Al‐Ali, H. K.;
    • Buxhofer‐Ausch, V.;
    • Alvarez‐Larrán, A.;
    • Akhani, S.;
    • Muñoz‐Carerras, R.;
    • Sheykin, Y.
    Publication type:
    Article
    19

    S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR.

    Published in:
    HemaSphere, 2022, v. 6, p. 96, doi. 10.1097/01.HS9.0000843672.56808.41
    By:
    • Verstovsek, S.;
    • Vannucchi, A.;
    • Gerds, A.;
    • Al‐Ali, H. K.;
    • Lavie, D.;
    • Kuykendall, A.;
    • Grosicki, S.;
    • Iurlo, A.;
    • Goh, Y. T.;
    • Lazaroiu, M.;
    • Egyed, M.;
    • Fox, M. L.;
    • McLornan, D.;
    • Perkins, A.;
    • Yoon, S.‐S.;
    • Gupta, V.;
    • Kiladjian, J.‐J.;
    • Donahue, R.;
    • Kawashima, J.;
    • Mesa, R.
    Publication type:
    Article
    20
    21
    22
    23

    Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature.

    Published in:
    Bone Marrow Transplantation, 2011, v. 46, n. 8, p. 1071, doi. 10.1038/bmt.2010.252
    By:
    • de Hosson, L. D.;
    • van de Warrenburg, B. P. C.;
    • Preijers, F. W. M. B.;
    • Blijlevens, N. M. A.;
    • van der Reijden, B. A.;
    • Kremer, H. P. H.;
    • Lefeber, D. J.;
    • Allebes, W. A.;
    • Al-Ali, H.;
    • Niederwieser, D. W.;
    • Schaap, N. P. M.;
    • Schattenberg, A. V. M. B.
    Publication type:
    Article
    24
    25
    26
    27
    28
    29
    30

    Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2016, v. 142, n. 1, p. 305, doi. 10.1007/s00432-015-2045-8
    By:
    • Kahl, C.;
    • Krahl, R.;
    • Becker, C.;
    • Al-Ali, H.;
    • Sayer, H.;
    • Schulze, A.;
    • Herold, M.;
    • Hänel, M.;
    • Scholl, S.;
    • Hochhaus, A.;
    • Uharek, L.;
    • Maschmeyer, G.;
    • Haehling, D.;
    • Junghanß, C.;
    • Peter, N.;
    • Kämpfe, D.;
    • Kettner, E.;
    • Heinicke, T.;
    • Fischer, T.;
    • Kreibich, U.
    Publication type:
    Article
    31
    32
    33
    34
    35
    36
    37

    Glycan synthesis: An update.

    Published in:
    Tropical Journal of Pharmaceutical Research, 2024, v. 23, n. 4, p. 783, doi. 10.4314/tjpr.v23i4.15
    By:
    • Abualassal, Qais;
    • Abudayeh, Zead;
    • Al-Najdawi, Manal;
    • Hussein-Al-Ali, Samer H.
    Publication type:
    Article
    38
    39
    40
    41
    42

    Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium.

    Published in:
    Cancer (0008543X), 2015, v. 121, n. 6, p. 876, doi. 10.1002/cncr.29145
    By:
    • Jabbour, Elias J.;
    • Garcia‐Manero, Guillermo;
    • Strati, Paolo;
    • Mishra, Asmita;
    • Al Ali, Najla H.;
    • Padron, Eric;
    • Lancet, Jeffrey;
    • Kadia, Tapan;
    • Daver, Naval;
    • O'Brien, Susan;
    • Steensma, David P.;
    • Sekeres, Mikkael A.;
    • Gore, Steven D.;
    • Dezern, Amy;
    • Roboz, Gail J.;
    • List, Alan F.;
    • Kantarjian, Hagop M.;
    • Komrokji, Rami S.
    Publication type:
    Article
    43
    44

    TP53 variant allele frequency and therapy‐related setting independently predict survival in myelodysplastic syndromes with del(5q).

    Published in:
    British Journal of Haematology, 2024, v. 204, n. 4, p. 1243, doi. 10.1111/bjh.19247
    By:
    • Tefferi, Ayalew;
    • Fleti, Farah;
    • Chan, Onyee;
    • Al Ali, Najla H.;
    • Al‐Kali, Aref;
    • Begna, Kebede H.;
    • Foran, James M.;
    • Badar, Talha;
    • Khera, Nandita;
    • Shah, Mithun;
    • Hiwase, Devendra;
    • Padron, Eric;
    • Sallman, David A.;
    • Pardanani, Animesh;
    • Arber, Daniel A.;
    • Orazi, Attilio;
    • Reichard, Kaaren K.;
    • He, Rong;
    • Ketterling, Rhett P.;
    • Gangat, Naseema
    Publication type:
    Article
    45
    46
    47
    48
    49
    50